Create Account | Sign In: Author or Forum

Search Symptoms

Category: Family Medicine | Internal Medicine | Preventive Medicine | Oncology | Radiology

Back to Blogs

Airport whole body scanners and radiation exposure - ACR statement

Author: Tamer M. Fouad, M.D. | Submitted: January 07, 2010. Updated: January 07, 2010.

Tamer M. Fouad, M.D.'s avatar

Amid concerns regarding terrorists targeting airliners using weapons less detectable by traditional means, the Transportation Security Administration (TSA) is ramping up deployment of whole body scanners at security checkpoints in U.S. airports. These systems produce anatomically accurate images of the body and can detect objects and substances concealed by clothing.

To date, TSA has deployed two types of scanning systems:

Millimeter wave technology uses low-level radio waves in the millimeter wave spectrum. Two rotating antennae cover the passenger from head to toe with low-level RF energy.

Backscatter technology uses extremely weak X-rays delivering less than 10 microRem of radiation per scan ─ the radiation equivalent one receives inside an aircraft flying for two minutes at 30,000 feet.

An airline passenger flying cross-country is exposed to more radiation from the flight than from screening by one of these devices. The National Council on Radiation Protection and Measurement (NCRP) has reported that a traveler would need to experience 2,500 backscatter scans per year to reach what they classify as a Negligible Individual Dose. The American College of Radiology (ACR) agrees with this conclusion.

The ACR is not aware of any evidence that either of the scanning technologies that the TSA is considering would present significant biological effects for passengers screened.

CITE THIS ARTICLE:
Tamer M. Fouad, M.D.. Airport whole body scanners and radiation exposure - ACR statement. Doctors Lounge Website. Available at: https://www.doctorslounge.com/index.php/blogs/page/316. Accessed August 22 2017.


Previous: New SBI and ACR recommendations - breast cancer screening should begin at age 40 Next: Rituximab drastically reduces efficacy of H1N1 vaccine in rheumatoid patients

Reader comments on this article are listed below. Review our comments policy.


Submit your opinion: